Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. / Bang, Anne K; Petersen, Jørgen H; Petersen, Peter M; Andersson, Anna-Maria; Daugaard, Gedske; Jørgensen, Niels.

I: International Journal of Radiation Oncology, Biology, Physics, Bind 75, Nr. 3, 2009, s. 672-6.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Bang, AK, Petersen, JH, Petersen, PM, Andersson, A-M, Daugaard, G & Jørgensen, N 2009, 'Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells', International Journal of Radiation Oncology, Biology, Physics, bind 75, nr. 3, s. 672-6. https://doi.org/10.1016/j.ijrobp.2008.11.057

APA

Bang, A. K., Petersen, J. H., Petersen, P. M., Andersson, A-M., Daugaard, G., & Jørgensen, N. (2009). Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. International Journal of Radiation Oncology, Biology, Physics, 75(3), 672-6. https://doi.org/10.1016/j.ijrobp.2008.11.057

Vancouver

Bang AK, Petersen JH, Petersen PM, Andersson A-M, Daugaard G, Jørgensen N. Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. International Journal of Radiation Oncology, Biology, Physics. 2009;75(3):672-6. https://doi.org/10.1016/j.ijrobp.2008.11.057

Author

Bang, Anne K ; Petersen, Jørgen H ; Petersen, Peter M ; Andersson, Anna-Maria ; Daugaard, Gedske ; Jørgensen, Niels. / Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. I: International Journal of Radiation Oncology, Biology, Physics. 2009 ; Bind 75, Nr. 3. s. 672-6.

Bibtex

@article{d2edf1506a3e11df928f000ea68e967b,
title = "Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells",
abstract = "PURPOSE: To study the effect of 16 Gy radiotherapy (RT) vs. 20 Gy RT on Leydig cell function in men treated with radiotherapy against carcinoma in situ (CIS) of the testis. METHODS AND MATERIALS: Fifty-one men who were treated between 1985 and 2005 were included. Fourteen men had been treated with 20 Gy and 37 with 16 Gy RT. Measurements of sex hormone-binding globulin and basic and stimulated testosterone, as well as luteinizing hormone levels were performed. RESULTS: The follow-up periods for the patients treated without additional chemotherapy were for the 20 Gy and 16 Gy group mean/median/min-max: 9.0/10.0/1.0-20.3 years and 4.0/3.1/0.4-14.1 years, respectively. During the follow-up period, men treated with 16 Gy RT had stable testosterone levels (-1.1%/year, p = 0.4), whereas men treated with 20 Gy had an annual decrease of 2.4% (p = 0.008). For the latter group, the testosterone decrease was most pronounced in the first 5 years, leveling off during the following 5 years. Additionally, more men treated with 20 Gy needed androgen substitution treatment. Our study showed an increased luteinizing hormone level for the men treated with 16 Gy, although this was not significant (p = 0.5). We anticipated a similar increase in the patients treated with 20 Gy but instead observed a decrease (-3.1%, p = 0.01). CONCLUSION: RT at 16 and 20 Gy seem to affect Leydig cell function differently, with 16 Gy RT better preserving testosterone levels and thus being preferred from an endocrinological point of view.",
author = "Bang, {Anne K} and Petersen, {J{\o}rgen H} and Petersen, {Peter M} and Anna-Maria Andersson and Gedske Daugaard and Niels J{\o}rgensen",
note = "Keywords: Adult; Carcinoma in Situ; Dose-Response Relationship, Radiation; Follicle Stimulating Hormone; Humans; Leydig Cells; Luteinizing Hormone; Male; Orchiectomy; Prospective Studies; Testicular Neoplasms; Testosterone; Time Factors",
year = "2009",
doi = "10.1016/j.ijrobp.2008.11.057",
language = "English",
volume = "75",
pages = "672--6",
journal = "International Journal of Radiation Oncology, Biology, Physics",
issn = "0360-3016",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells

AU - Bang, Anne K

AU - Petersen, Jørgen H

AU - Petersen, Peter M

AU - Andersson, Anna-Maria

AU - Daugaard, Gedske

AU - Jørgensen, Niels

N1 - Keywords: Adult; Carcinoma in Situ; Dose-Response Relationship, Radiation; Follicle Stimulating Hormone; Humans; Leydig Cells; Luteinizing Hormone; Male; Orchiectomy; Prospective Studies; Testicular Neoplasms; Testosterone; Time Factors

PY - 2009

Y1 - 2009

N2 - PURPOSE: To study the effect of 16 Gy radiotherapy (RT) vs. 20 Gy RT on Leydig cell function in men treated with radiotherapy against carcinoma in situ (CIS) of the testis. METHODS AND MATERIALS: Fifty-one men who were treated between 1985 and 2005 were included. Fourteen men had been treated with 20 Gy and 37 with 16 Gy RT. Measurements of sex hormone-binding globulin and basic and stimulated testosterone, as well as luteinizing hormone levels were performed. RESULTS: The follow-up periods for the patients treated without additional chemotherapy were for the 20 Gy and 16 Gy group mean/median/min-max: 9.0/10.0/1.0-20.3 years and 4.0/3.1/0.4-14.1 years, respectively. During the follow-up period, men treated with 16 Gy RT had stable testosterone levels (-1.1%/year, p = 0.4), whereas men treated with 20 Gy had an annual decrease of 2.4% (p = 0.008). For the latter group, the testosterone decrease was most pronounced in the first 5 years, leveling off during the following 5 years. Additionally, more men treated with 20 Gy needed androgen substitution treatment. Our study showed an increased luteinizing hormone level for the men treated with 16 Gy, although this was not significant (p = 0.5). We anticipated a similar increase in the patients treated with 20 Gy but instead observed a decrease (-3.1%, p = 0.01). CONCLUSION: RT at 16 and 20 Gy seem to affect Leydig cell function differently, with 16 Gy RT better preserving testosterone levels and thus being preferred from an endocrinological point of view.

AB - PURPOSE: To study the effect of 16 Gy radiotherapy (RT) vs. 20 Gy RT on Leydig cell function in men treated with radiotherapy against carcinoma in situ (CIS) of the testis. METHODS AND MATERIALS: Fifty-one men who were treated between 1985 and 2005 were included. Fourteen men had been treated with 20 Gy and 37 with 16 Gy RT. Measurements of sex hormone-binding globulin and basic and stimulated testosterone, as well as luteinizing hormone levels were performed. RESULTS: The follow-up periods for the patients treated without additional chemotherapy were for the 20 Gy and 16 Gy group mean/median/min-max: 9.0/10.0/1.0-20.3 years and 4.0/3.1/0.4-14.1 years, respectively. During the follow-up period, men treated with 16 Gy RT had stable testosterone levels (-1.1%/year, p = 0.4), whereas men treated with 20 Gy had an annual decrease of 2.4% (p = 0.008). For the latter group, the testosterone decrease was most pronounced in the first 5 years, leveling off during the following 5 years. Additionally, more men treated with 20 Gy needed androgen substitution treatment. Our study showed an increased luteinizing hormone level for the men treated with 16 Gy, although this was not significant (p = 0.5). We anticipated a similar increase in the patients treated with 20 Gy but instead observed a decrease (-3.1%, p = 0.01). CONCLUSION: RT at 16 and 20 Gy seem to affect Leydig cell function differently, with 16 Gy RT better preserving testosterone levels and thus being preferred from an endocrinological point of view.

U2 - 10.1016/j.ijrobp.2008.11.057

DO - 10.1016/j.ijrobp.2008.11.057

M3 - Journal article

C2 - 19250763

VL - 75

SP - 672

EP - 676

JO - International Journal of Radiation Oncology, Biology, Physics

JF - International Journal of Radiation Oncology, Biology, Physics

SN - 0360-3016

IS - 3

ER -

ID: 20009787